Dupilumab has demonstrated significant efficacy in eosinophilic esophagitis [11, 12] by reducing eosinophilic inflammation through inhibition of IL-4 and IL-13 signaling pathways [13], and thus could theoretically exert similar beneficial effects in EoEM. This evidence concerns the gene IL13 and eosinophilic esophagitis.